FDA Says Popular Nasal Decongestant Not Effective Treatment For Congestion

FDA Says Popular , Nasal Decongestant , Not Effective Treatment For Congestion.
Associated Press reports that government experts
found that the number one decongestant in
the United States does not alleviate a stuffy nose. .
Associated Press reports that government experts
found that the number one decongestant in
the United States does not alleviate a stuffy nose. .
On September 12, advisers for the Food and
Drug Administration voted unanimously
against the effectiveness of phenylephrine.
Phenylephrine is found in a number
of popular over-the-counter products,
including Sudafed, Allegra and Dayquil.
Modern studies,
when well conducted,
are not showing any improvement
in congestion with phenylephrine, Dr. Mark Dykewicz, Allergy specialist at the Saint Louis
University School of Medicine, via Associated Press.
AP reports that a team of outside advisers
were assembled by the FDA to take a closer
look at the effectiveness of phenylephrine.
Phenylephrine became the key ingredient in decongestants in 2006, when pseudoephedrine
was ordered to be moved behind pharmacy counters.
Phenylephrine became the key ingredient in decongestants in 2006, when pseudoephedrine
was ordered to be moved behind pharmacy counters.
The change came after a 2006 law called
for the change, as pseudoephedrine can
be used to produce methamphetamine. .
The change came after a 2006 law called
for the change, as pseudoephedrine can
be used to produce methamphetamine. .
AP reports that pending the FDA's decision,
drugmakers like Johnson & Johnson and Bayer could
be ordered to pull oral medications with phenylephrine. .
AP reports that pending the FDA's decision,
drugmakers like Johnson & Johnson and Bayer could
be ordered to pull oral medications with phenylephrine. .
According to the FDA's panel of experts,
consumers would need to be educated on
remaining options for treating congestion.
Patients require and deserve
medications that treat their
symptoms safely and effectively
and I don’t believe that
this medication does that, Jennifer Schwartzott, the patient representative
on the FDA panel, via Associated Press